ArticleJournal of translational medicine2026
TLR4 promotes ESCC progression by driving inflammation and metabolic reprogramming through SLC39A10-mediated zinc homeostasis.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- An AI-integrated organoid platform enables high-throughput functional evaluation of bioactive metal ions.Bioactive materials · 2026Article
- Zinc sulfate modulates the C3H10T1/2 mesenchymal stem cell line secretome and NFκB signaling during inflammation to influence selected immune cell responses.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundToll-like receptor 4 (TLR4), a key pattern recognition receptor in innate immunity, is frequently overexpressed in various malignancies including esophageal squamous cell carcinoma (ESCC). While TLR4’s oncogenic potential has been established, its functional contribution to ESCC pathogenesis remains incompletely understood, and the therapeutic potential of TLR4 signaling inhibition warrants further investigation.
methodsComprehensive expression profiling of TLR4 and SLC39A10 was performed in: (1) clinical ESCC specimens, (2) established ESCC cell lines, and (3) 4-nitroquinoline 1-oxide (4-NQO)-induced spontaneous and xenograft tumor models. Functional characterization included TLR4 genetic ablation, zinc chelation experiments, and systematic analysis of glycolytic metabolism. Glycolytic flux was quantified through extracellular acidification rate (ECAR), oxygen consumption rate (OCR), glucose uptake efficiency, and lactate secretion assays. Zinc homeostasis regulation was examined using pharmacological modulators combined with SLC39A10 genetic silencing approaches.
resultsTLR4 activation upregulated SLC39A10 expression, resulting in intracellular zinc accumulation that simultaneously potentiated NF-κB-dependent inflammatory signaling and HIF1α-mediated glycolytic activation. Genetic TLR4 ablation significantly attenuated tumorigenesis in vivo, while SLC39A10 knockdown abrogated TLR4’s oncogenic effects.
conclusionsOur study identifies a previously unrecognized TLR4/SLC39A10/zinc pathway that drives ESCC progression through dual modulation of inflammatory and metabolic pathways. These findings provide the first experimental evidence connecting zinc homeostasis to TLR4-mediated metabolic reprogramming in cancer, revealing novel therapeutic targets for ESCC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.